Key result
CTLA4Ig prevents fatal multiorgan tissue destruction in CTLA-4-deficient mice, but disease returns after cessation.
Answers are grounded in this paper and cite their sources.
Demonstrates that CTLA4Ig prevents fatal multiorgan destruction and abnormal T cell proliferation in CTLA-4-deficient mice, indicating CD28-B7 signaling drives this disease.
Mice lacking CTLA-4 develop a fatal spontaneous lymphoproliferative disease with massive lymphocytic infiltrates and tissue destruction in many organs. CTLA-4-deficient (-/-) splenocytes and lymph node cells proliferate without added stimuli in vitro. We report here that CTLA4Ig treatment of CTLA-4 -/- mice prevents lymphoproliferation and fatal multiorgan tissue damage in vivo and proliferation of CTLA-4 -/- splenocytes and lymph node cells in vitro. Therefore, stimulation via CD28-B7 interactions appears necessary for CTLA-4 -/- T cell proliferation and the production of lymphoproliferative disease in vivo. When CTLA4Ig treatment is terminated, CTLA-4 -/- T cells become activated and lymphoproliferative disease develops. The lack of long term protective effects of CTLA4Ig treatment suggests that CTLA-4 is needed for the induction and or maintenance of tolerance.
No takes yet. Share an insight, caveat, or question.
Tivol et al. (1997) studied CTLA-4 deficiency and spontaneous lymphoproliferative disease. CTLA4Ig was evaluated on Prevention of lymphoproliferation and fatal multiorgan tissue damage. CTLA4Ig treatment in CTLA-4-deficient mice prevents lymphoproliferation and fatal multiorgan tissue destruction in vivo, though disease develops upon treatment termination.
Synapse has enriched 10 related papers. Consider them for comparative context: